Patheon IncTSX: PTI

Patheon announces fourth quarter and year end results

· Issued by Patheon Inc via CNW
TORONTO, Dec. 13 /CNW/ - Patheon (TSX:PTI), a leading global provider of
drug development and manufacturing services to the international
pharmaceutical industry, announces its results for the fourth quarter and year
ended October 31, 2005. (All amounts are in U.S. dollars unless otherwise
indicated.)

Fourth Quarter
-  Revenues increased 48% to $181.9 million;
-  Internal revenue growth was 15%; strategic growth (MOVA acquisition)
   was $40.9 million;
-  EBITDA increased 94% to $26.2 million; the EBITDA margin was 14.4%
   versus 11.0% a year ago (12.8% before U.K. repositioning costs);
-  Cash provided from operations increased 70% to $18.7 million;
-  Free cash flow increased to $6.4 million from $0.9 million last year;
-  Net earnings (excluding the impact of a one-time gain in 2005 and U.K.
   repositioning costs in 2004) increased 17% to $5.4 million; basic EPS
   was 5.8 cents versus 8.9 cents a year ago. Reported net earnings
   increased 180% to $8.4 million; basic EPS was 9.3 cents versus
   5.8 cents a year ago.

Full Year
-  Revenues increased 48% to $698.3 million;
-  Internal revenue growth was 17%; strategic growth (MOVA acquisition)
   was $149.3 million;
-  EBITDA rose 104% to $98.0 million; the EBITDA margin was 14.0% versus
   10.2% a year ago (11.2% before U.K. repositioning costs);
-  Cash provided from operations increased 81% to $73.5 million;
-  Free cash flow increased to $12.1 million versus negative free cash
   flow of $22.2 million a year ago;
-  Net earnings (excluding the impact of a one-time gain in 2005 and U.K.
   repositioning costs in 2004) increased 35% to $18.6 million; basic EPS
   was 21.4 cents versus 26.7 cents a year ago. Reported net earnings
   increased 102% to $21.6 million; basic EPS was 24.9 cents versus
   20.7 cents a year ago.

"Fiscal 2005 was a successful year for our Rx commercial and PDS
operations, but was clearly challenging due to a number of issues that
affected the performance of our MOVA operations as well as our Whitby site,"
commented Robert C. Tedford, Chief Executive Officer of Patheon Inc.
"The issues at MOVA included the shortage of client-supplied active
pharmaceutical ingredient (API) for the large-volume Omnicef(R) product, the
suspension of manufacturing of that same product in response to a FDA Warning
Letter and a decrease in volumes for a newly launched product," continued Mr.
Tedford. "These challenges resulted in lower capacity utilization and
operating margins at MOVA in the second half of the year and a negative impact
on earnings per share.
"At Whitby, we faced challenges as a result of significantly lower-than-
anticipated volumes in connection with a new product launch as well as
capacity constraints relating to increased demand for certain OTC products,"
added Mr. Tedford.
"With regards to our North American (excluding MOVA) and European
operations, we are reporting strong internal growth of 17% in fiscal 2005
driven by our high-quality Rx manufacturing and drug development (PDS)
services," said Mr. Tedford. "In particular, we would like to highlight the
sustained strength of commercial volumes from a number of successful new
product launches in Canada, the growing contribution from our Rx operations in
North America, the year-over-year improvement in operating margins at our
Swindon operations, the continuing strong growth of our lyophilization
business in Europe and the momentum that continues to build in our global PDS
business.
"We are pleased with the continued success of our PDS strategy in both
North America and Europe," said Mr. Tedford. "Our PDS business had another
excellent year in 2005 with 31% growth in number of projects and 5 NDA
approvals, including one subsequent to year-end. At year-end, we had a total
of 147 projects in our pipeline including 6 drug candidates at the NDA stage,
of which 4 are in line for approval as soon as fiscal 2006.
"While not meeting our full expectations, revenues in fiscal 2005
increased 48% to $698.3 million and the EBITDA margin improved to 14.0% from
10.2% a year ago as a result of the strategic revenues from MOVA and the
improved revenue contribution in our base business," added Mr. Tedford.
"Reported earnings per share, which amounted to 24.9 cents per share compared
with 20.7 cents in 2004, were affected by the disappointing performance at our
MOVA operations in the second half of the year and at our Whitby operations.
On other key metrics for our Company - cash from operations, free cash flow
and ratio of long-term debt to shareholders' equity - we are pleased to report
a significant improvement over last year."

Operating Review

For the year ended October 31, 2005, consolidated revenues increased by
48% or $228.1 million. This increase reflects internal growth of 17% or
$78.8 million driven by Rx manufacturing and PDS services, and strategic
growth of $149.3 million from the MOVA operations acquired on December 23,
2004.
Revenues from prescription (Rx) manufacturing, including MOVA, increased
by 65% or $195.8 million; PDS services increased by 38% or $25.3 million; and
over-the-counter (OTC) manufacturing increased by 7% or $7.0 million. Revenues
from North American operations (including MOVA) rose by 67% or $197.9 million,
and European operations by 17% or $30.2 million.
For the twelve months of 2005, Rx activities, including MOVA, accounted
for 71% of revenues, PDS for 13% and OTC for 16%. North American and European
operations accounted for 71% and 29% of revenues, respectively.
Full-year EBITDA amounted to $98.0 million, an increase of 104% or
$49.9 million over a year ago. The EBITDA margin for the year was 14.0%
compared with 10.2% a year earlier (11.2% before U.K. repositioning costs),
largely attributable to higher Rx volumes and improved revenue contribution
both in North America and in Europe.
In North America, Rx revenues were driven by the added contribution of
MOVA particularly in the first and second quarters, and new product launches
at the Toronto high-potency site. MOVA margins, which were higher than those
of other operations in the Company's network in the first half of 2005, were
impacted in the second half of the year by lower capacity utilization.
In Europe, Rx revenues were enhanced by continued growth in commercial
volumes and the PDS business. As expected, Swindon was EBITDA-positive in
fiscal 2005.
Net earnings, excluding the impact of a one-time gain in 2005 and U.K.
repositioning costs in 2004, increased 35% to $18.6 million, and basic EPS was
21.4 cents versus 26.7 cents a year ago. Reported net earnings increased by
102% to $21.6 million in fiscal 2005. Basic earnings per share of 24.9 cents,
including a one-time gain of 3 cents per share on the sale of land in
Bourgoin, France, compared with 20.7 cents per share in the previous year
after U.K. repositioning costs. Earnings per share in fiscal 2005 were
impacted by the temporary suspension of production of the Omnicef(R) product
at MOVA (2 cents per share), lower capacity utilization at MOVA in the second
half of the year and at Whitby, higher non-cash charges and acquisition-
related expenses as well as a 69% increase in the average number of shares
outstanding year over year due to shares issued in connection with the MOVA
acquisition.
In the fourth quarter, revenues increased 48% or $59.1 million. This
increase reflects internal growth of 15% or $18.2 million driven by Rx
manufacturing and PDS services in the base business, and strategic growth of
$40.9 million from MOVA. As a result of higher revenue contribution from the
base business in both North America and Europe, EBITDA increased 94% to
$26.2 million, and the EBITDA margin rose to 14.4% from 11.0% a year ago. Net
earnings, excluding the impact of the one-time gain on sale of land in France
in 2005 and U.K. repositioning costs in 2004, increased 17% to $5.4 million,
and basic EPS was 5.8 cents versus 8.9 cents a year ago. Reported net earnings
increased 180% to $8.4 million, and basic EPS was 9.3 cents versus 5.8 cents a
year ago.
The Company's results are sensitive to changes in the C$-US$ exchange
rate. The average exchange rate in 2005 was 1.22 (C$0.82). Based on our
current US$ net inflows, for each cent change in the C$-US$ exchange rate, the
impact on annual EPS is slightly less than one cent per share. The Company has
entered into forward exchange contracts to sell U.S. dollars and purchase
Canadian dollars. The mark-to-market value of these financial instruments as
at October 31, 2005 was an unrealized gain of $0.2 million.
Cash provided from operations increased 81% to $73.5 million in fiscal
2005, reflecting contributions from both existing and MOVA operations. During
the year, the Company generated free cash flow of $12.1 million compared with
negative free cash flow of $22.2 million last year. Cash and cash equivalents
at October 31, 2005 were $25.5 million including restricted cash at MOVA of
$3.6 million, compared with $7.6 million at the end of the 2004 fiscal year.
At October 31, 2005, the Company's ratio of consolidated interest bearing
long term debt (including current portion) to shareholders' equity was 53.4%
compared with 56.1% one year ago.
The Company has recently received commitments from a syndicate of U.S.
and Canadian financial institutions for new credit facilities in the aggregate
amount of $290 million. The new loans, which are being used to replace debt
facilities in MOVA assumed as part of the acquisition in December, 2004 and to
replace the one-year bridge facility provided by a group of Canadian lenders
also at the time of the acquisition, will provide Patheon with more efficient,
longer tenure credit facilities for its North American operations.
The new credit facilities comprise revolving facilities in the aggregate
amount of $75 million and two term loans in the aggregate amount of
$215 million. The term loans will consist of a five-year loan in the amount of
$50 million and a six-year term loan in the amount of $165 million. The new
facilities, which are expected to be completed before December 22, 2005, will
be secured by the North American assets of Patheon and its subsidiaries,
including those in Puerto Rico.
In connection with the new facilities, deferred financing charges and pre-
payment penalties totalling approximately $7.6 million related to the
previous lending arrangements will be charged to earnings in the first quarter
of fiscal 2006. It is expected that future operations will benefit from the
lower lending costs under the new financing arrangements.

Outlook

"We expect a modest improvement in operating results in fiscal 2006, with
the second half of the year stronger than the first," continued Mr. Tedford.
"We further expect that net earnings and earnings per share in 2006 will be
similar to 2005 levels, excluding the impact of the one-time gain in the
fourth quarter of 2005 and the anticipated write-off of deferred financing
costs and pre-payment penalties in the first quarter of 2006.
"We anticipate that the first quarter of 2006 will be impacted by normal
seasonality and production shutdowns, as well as lower production levels
caused by the temporary suspension of production of the Omnicef(R) product
that is expected to have an additional impact of approximately 3 cents per
share," commented Mr. Tedford. "In addition, the one-time write-off of
deferred financing costs and pre-payment penalties of $7.6 million will have a
one-time negative impact on earnings. First-quarter results, before the impact
of the one-time write-off, will also reflect a full quarter of amortization,
depreciation and interest expenses related to the MOVA acquisition compared to
five weeks in the first quarter of 2005.
"We regard 2006 to be a transition year," commented Mr. Tedford. "Our
2006 initiatives will include addressing the short-term challenges at MOVA,
expanding our cephalosporin capacity in Swindon, completing the transfer of
two groups of products to our European operations, addressing the challenges
faced by our Canadian OTC sites including Whitby, expanding our PDS operations
in Puerto Rico and establishing an initial PDS presence in India," commented
Mr. Tedford. "We will also focus on early stage and advanced stage
opportunities for new business at both MOVA and our other operations with a
view to increasing production volumes in fiscal 2007 and beyond.
"The combination of oral cephalosporin capabilities at our Carolina
facility, the existing sterile cephalosporin capabilities at Swindon and the
new lyophilization plant dedicated to cephalosporin products that we are
constructing in Swindon will allow us to provide a full range of dosage forms
for this important category of antibiotics," explained Mr. Tedford. "The new
facility at Swindon, scheduled for completion by the end of fiscal 2006,
represents an investment of approximately 22 million euros. Our client is
providing a substantial portion of the financing.
"In Europe, we will continue to integrate new Rx products into our sites
in Italy and France as part of the transfer of two groups of products from two
clients who are restructuring their respective facilities in Europe,"
continued Mr. Tedford. "As part of this initiative, we will be establishing
high-potency capabilities in Bourgoin by investing approximately 10 million
euros at this site in 2006 and 2007.
In Canada, our sites that focus on manufacturing OTC products are facing
significant challenges to achieve or maintain satisfactory levels of
profitability," said Mr. Tedford. "This will be an area of particular focus
for management in fiscal 2006.
"We expect to continue to expand our successful PDS operations by
focusing our efforts on two new initiatives," concluded Mr. Tedford. "In
Puerto Rico, we will expand our existing PDS capabilities by encouraging
clients to conduct PDS research and development in a favourable tax
jurisdiction. We will also establish a presence in India to explore
opportunities to provide PDS services from that country. This initiative in
India is not expected to generate positive financial benefits in fiscal 2006.
"In summary, we expect our 2006 results to stabilize after a difficult
year in 2005," said Mr. Tedford. "We anticipate that growth rates and
profitability will improve in 2007 to the extent that our initiatives in 2006
are implemented successfully."


FORWARD-LOOKING STATEMENTS: CAUTIONARY NOTE

This news release contains forward-looking statements which reflect
management's expectations regarding the Company's future growth of operations,
performance (both operational and financial) and business opportunities.
PLEASE SEE THE CAUTIONARY NOTE AT THE END OF THE MANAGEMENT DISCUSSION AND
ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS ATTACHED TO AND
FORMING PART OF THIS NEWS RELEASE.

ABOUT PATHEON
Patheon (TSX:PTI; www.patheon.com) is a leading global provider of drug
development and manufacturing services to the international pharmaceutical
industry. Patheon operates a network of 14 facilities in the United States,
Canada and Europe, employing more than 5,900 people and serving a client base
of 180 pharmaceutical and biotechnology companies.


<<
Consolidated Statements of Earnings
(unaudited)

                          Three months ended         Twelve months ended
                                  October 31,                 October 31,
                                         %                           %
                       2005      2004 change       2005      2004 change
-------------------------------------------------------------------------
(in thousands of
 U.S. dollars,
 except per
 share amounts)           $         $                 $         $
-------------------------------------------------------------------------

Revenues            181,893   122,821   48.1%   698,318   470,259   48.5%
Operating expenses  155,371   106,626   45.7%   598,828   416,374   43.8%
Repositioning
 expenses (note 13)       -     2,265                 -     4,407
Stock-based
 compensation           319       445  -28.3%     1,528     1,373   11.3%
                   -------------------------- ---------------------------
Earnings before
 depreciation and
 amortization,
 interest, gain on
 sale of land and
 income taxes        26,203    13,485   94.3%    97,962    48,105  103.6%
                   -------------------------- ---------------------------
(as a % of
 revenues)            14.4%     11.0%             14.0%     10.2%

Depreciation          7,806     5,951   31.2%    33,351    22,765   46.5%
Amortization of
 intangible assets
 (note 3)             3,443         -            11,188         -
Interest              4,652     1,798  158.7%    16,449     5,609  193.3%
Amortization of
 deferred financing
 costs (note 11)      1,303         -             4,824         -
Write-off of
 deferred financing
 costs (note 11)          -         -             2,010         -
Gain on sale of
 land (note 14)      (4,587)        -            (4,587)        -
                   -------------------------- ---------------------------
Earnings before
 income taxes        13,586     5,736  136.9%    34,727    19,731   76.0%
Provision for
 income taxes         5,207     2,739   90.1%    13,106     9,053   44.8%
                   -------------------------- ---------------------------
Net earnings for
 the period           8,379     2,997  179.6%    21,621    10,678  102.5%
                   -------------------------- ---------------------------
                   -------------------------- ---------------------------
(as a % of
 revenues)             4.6%      2.4%              3.1%      2.3%

Earnings per share
 (note 2)
  Basic                 9.3       5.8   60.3%      24.9      20.7   20.3%
                      cents     cents             cents     cents
                   -------------------------- ---------------------------
  Diluted               9.3       5.8   60.3%      24.8      20.6   20.4%
                      cents     cents             cents     cents
                   -------------------------- ---------------------------
Average number of
 shares outstanding
 during period:
  Basic
   (in thousands)    92,846    51,556   80.1%    86,828    51,521   68.5%
                   -------------------------- ---------------------------
  Diluted
   (in thousands)    93,076    51,846   79.5%    87,206    51,967   67.8%
                   -------------------------- ---------------------------

see accompanying notes



Consolidated Statements of Retained Earnings
(unaudited)

                                          Twelve months ended October 31,
                                                      2005          2004
-------------------------------------------------------------------------
(in thousands of U.S. dollars)                           $             $
-------------------------------------------------------------------------

Retained earnings, beginning of the year            76,629        65,951
Net earnings for the year                           21,621        10,678
                                               --------------------------
Retained earnings, end of year                      98,250        76,629
                                               --------------------------
                                               --------------------------

see accompanying notes



Consolidated Balance Sheets
(unaudited)
                                                     As at         As at
                                                October 31,   October 31,
                                                      2005          2004
-------------------------------------------------------------------------
(in thousands of U.S. dollars)                           $             $
-------------------------------------------------------------------------

Assets
Current
  Cash and cash equivalents (note 5)                25,488         7,626
  Certificate of deposit (note 5)                    4,824             -
  Accounts receivable                              143,646        95,305
  Inventories                                       72,818        58,763
  Income taxes receivable                                -         1,029
  Prepaid expenses and other                         4,258         2,768
                                               --------------------------
Total current assets                               251,034       165,491
                                               --------------------------

Capital assets, net                                474,793       331,725
Future tax assets                                   21,368        15,800
Goodwill (note 3)                                  180,665         2,837
Intangible assets, net (note 3)                    110,095             -
Deferred pre-operating and financing costs          12,342         5,498
Investment                                           1,271         1,232
                                               --------------------------
                                                 1,051,568       522,583
                                               --------------------------
                                               --------------------------

Liabilities and Shareholders' equity
Current
  Bank indebtedness                                 14,357        21,454
  Accounts payable and accrued liabilities         129,067       105,567
  Income taxes payable                               5,650             -
  Current portion of long-term debt (note 10)      124,642        11,146
                                               --------------------------
Total current liabilities                          273,716       138,167
                                               --------------------------

Long-term debt (note 10)                           163,899       113,116
Other long-term liabilities                         22,755        21,660
Deferred revenues (notes 3, 12)                     14,587             -
Future tax liabilities                              36,760        28,242
                                               --------------------------
Total liabilities                                  511,717       301,185
                                               --------------------------

Shareholders' equity
  Share capital (note 4)                           400,594       118,954
  Contributed surplus                                2,901         1,373
  Retained earnings                                 98,250        76,629
  Cumulative translation adjustment                 38,106        24,442
                                               --------------------------
Total shareholders' equity                         539,851       221,398
                                               --------------------------
                                                 1,051,568       522,583
                                               --------------------------
                                               --------------------------

see accompanying notes



Consolidated Statements of Cash Flows
(unaudited)

                              Three months ended     Twelve months ended
                                      October 31,             October 31,
                                2005        2004        2005        2004
-------------------------------------------------------------------------
(in thousands of U.S. dollars,
 except per share amounts)         $           $           $           $
-------------------------------------------------------------------------
Cash provided by (used in):
Operating activities
  Net earnings for the period  8,379       2,997      21,621      10,678
  Add (deduct) charges to
   operations not requiring
   a current cash payment
    Depreciation and
     amortization             12,552       5,951      49,363      22,765
    Write-off of deferred
     financing costs (note 11)     -           -       2,010           -
    Employee future benefits     244         881       1,639       2,688
    Future income taxes        1,971         729       2,642       2,384
    Loss on sale of
     investment                    -          33           -          33
    Gain on sale of land
     (note 14)                (4,587)          -      (4,587)          -
    Equipment write-down
     (note 13)                     -         (79)          -         671
    Stock-based compensation     319         445       1,528       1,373
    Amortization of deferred
     revenues                   (280)          -        (898)          -
    Other                         52           -         217           -
                           ----------------------------------------------
Cash provided from
 operations                   18,650      10,957      73,535      40,592
Net change in non-cash
 working capital balances
 related to operations         5,674       9,658      (4,640)       (173)
                           ----------------------------------------------
Cash provided by operating
 activities                   24,324      20,615      68,895      40,419
                           ----------------------------------------------

Investing activities
  Acquisition of MOVA
   Pharmaceutical Corporation
   (note 3)                    2,698           -    (211,823)          -
  Additions to capital assets
   - sustaining               (6,734)     (3,191)    (16,062)    (11,232)
   - project-related         (11,177)    (16,492)    (40,730)    (51,372)
  Proceeds on sale of land
   (note 14)                   4,748           -       4,748           -
  Proceeds on sale of
   investment                      -         265           -         265
  Redemption of certificate
   of deposit                      -           -         391           -
  Increase (decrease) in
   deferred pre-operating
   and financing costs          (700)         90     (12,700)     (1,422)
                           ----------------------------------------------
Cash used in investing
 activities                  (11,165)    (19,328)   (276,176)    (63,761)
                           ----------------------------------------------

Financing activities
  Increase (decrease) in
   bank indebtedness           1,536       4,527      (6,195)      8,246
  Increase in term loans      46,355      13,285     341,445      74,588
  Repayment of long-term
   debt and other long-term
   liabilities               (55,667)    (15,149)   (304,838)    (61,137)
  Increase in deferred
   revenues (note 12)              -           -       8,271           -
  Proceeds on issue of
   common shares before costs      -           -     199,241          22
  Share issue costs                -           -      (8,947)          -
                           ----------------------------------------------
Cash provided by (used in)
 financing activities         (7,776)      2,663     228,977      21,719
                           ----------------------------------------------
Effect of exchange rate
 changes on cash and cash
 equivalents                   1,139         260      (3,834)         79
                           ----------------------------------------------

Net increase (decrease) in
 cash and cash equivalents
 during the period             6,522       4,210      17,862      (1,544)
Cash and cash equivalents,
 beginning of period          18,966       3,416       7,626       9,170
                           ----------------------------------------------
Cash and cash equivalents,
 end of period                25,488       7,626      25,488       7,626
                           ----------------------------------------------
                           ----------------------------------------------

see accompanying notes



      Notes to Unaudited Consolidated Financial Statements for
                   the Year Ended October 31, 2005
         (Dollar information in tabular form is expressed in
                     thousands of U.S. dollars)

1.  Accounting policies

The accompanying consolidated financial statements have been prepared by
the Company in accordance with Canadian generally accepted accounting
principles on a basis consistent with those followed in the most recent
audited financial statements. These consolidated financial statements do
not include all the information and footnotes required by generally
accepted accounting principles for annual financial statements and
therefore should be read in conjunction with the audited consolidated
financial statements and notes included in the Company's Annual Report
for the year ended October 31, 2004.

2.  Earnings per share

The following is a reconciliation of the weighted average number of basic
and diluted shares:

                                           Three months ended October 31,
                                                      2005          2004
-------------------------------------------------------------------------
Weighted average number of common shares
 outstanding                                    92,845,688    51,555,822
Effect of dilutive stock options                   230,179       290,574
-------------------------------------------------------------------------
Weighted average number of common shares
 outstanding - diluted                          93,075,867    51,846,396
-------------------------------------------------------------------------
-------------------------------------------------------------------------


                                          Twelve months ended October 31,
                                                      2005          2004
-------------------------------------------------------------------------
Weighted average number of common shares
 outstanding                                    86,827,570    51,520,576
Effect of dilutive stock options                   378,029       446,290
-------------------------------------------------------------------------
Weighted average number of common shares
 outstanding - diluted                          87,205,599    51,966,866
-------------------------------------------------------------------------
-------------------------------------------------------------------------

3.  Acquisition of MOVA Pharmaceutical Corporation

On December 23, 2004, the Company completed the acquisition of MOVA
Pharmaceutical Corporation and MOVA Investments, Inc. (collectively
"MOVA"), a leading U.S. prescription pharmaceutical contract manufacturer
located in Puerto Rico, U.S.A.

The purchase price for the shares of MOVA was based on an enterprise
value for MOVA at closing of $350,000,000.  The Company issued 12,684,866
common shares to the shareholders of MOVA in satisfaction of $81,500,000
of the purchase price. The Company assumed approximately $133,300,000 in
debt and related costs, and paid $135,200,000 in cash at closing.

The agreement also provided for two earn-out arrangements relating to
MOVA's operating results for two specific periods. The maximum amounts
for the first and second earn-outs were $65 million and $26 million,
respectively. The Company placed into escrow $87.8 million to support
potential payments under the earn-out arrangements. An agreement was
reached with the former MOVA shareholders to pay the full amount of the
first earn-out arrangement and $65 million was disbursed from escrow on
June 23, 2005. It was determined that no amount was payable under the
second earn-out and the remaining funds held in escrow were released to
the Company and applied to reduce debt.

The acquisition has been accounted for using the purchase method and the
accompanying consolidated financial statements include the results of
operations from the date of purchase. The purchase price was allocated in
the accounts based on the fair value of the assets acquired as follows:

                                                               ----------
                                                                       $
                                                               ----------
Current assets                                                    62,176
Capital assets                                                   128,050
Other long term assets                                             1,719
Intangible assets                                                116,274
Goodwill                                                         170,161
Current liabilities                                              (34,430)
Deferred revenues                                                 (7,096)
Future tax liabilities                                            (3,402)
                                                               ----------
Net assets acquired before assumed debt                          433,452
Less: debt assumed                                              (133,333)
                                                               ----------
Net assets acquired                                              300,119
                                                               ----------
                                                               ----------

Intangible assets, which represent the value assigned to client
contracts, are being amortized on a straight-line basis over nine years.

The purchase price consideration was as follows:

                                                               ----------
                                                                       $
                                                               ----------
Cash consideration                                               208,489
Transaction costs                                                  3,334
                                                               ----------
Total cash consideration                                         211,823
Value of 12,684,866 common shares issued to shareholders
 of MOVA                                                          88,296
                                                               ----------
Total consideration                                              300,119
                                                               ----------
                                                               ----------

In accordance with generally accepted accounting principles, the value of
the 12,684,866 common shares was determined based on the average market
price of the Company's common shares for the two trading days prior to
the announcement of the transaction and the two trading days following
the announcement.

4.  Share capital

The following table summarizes information on share capital and related
matters at October 31, 2005:

                                               Outstanding   Exercisable
Common shares                                   92,845,688
Common share stock options                       3,886,840     3,145,990

On December 23, 2004, the Company completed a public offering of
26,000,000 common shares for gross proceeds of approximately
$181.0 million (net proceeds of $172.7 million after offering costs).
The Company also on December 23, 2004, issued 12,684,866 common shares to
the shareholders of MOVA in satisfaction of $81.5 million of the purchase
price of the acquisition.

On January 11, 2005, the underwriters of the public offering on
December 23, 2004, exercised the over-allotment option granted to
purchase an additional 2,600,000 common shares for gross proceeds of
approximately $18.3 million (net proceeds of $17.5 million after offering
costs).

5.  Cash and cash equivalents, Certificate of deposit

The Certificate of deposit of $4,824,000 and $3,615,000 of the amount
reported as cash and cash equivalents are restricted cash and are held in
support of certain debt agreements of MOVA.

6.  Segmented information

The Company is organized and managed as a single business segment, being
the provider of commercial manufacturing and pharmaceutical development
services.

North American and European operations consist of:

                                  Three months ended October 31, 2005
                           ----------------------------------------------
                              Canada         USA      Europe       Total
                                   $           $           $           $
-------------------------------------------------------------------------
Revenues
Canada                        11,339         476         202      12,017
USA                           37,487      68,913       2,307     108,707
Europe                         8,302         371      51,088      59,761
Other geographic areas           582         103         723       1,408
-------------------------------------------------------------------------
Total revenues                57,710      69,863      54,320     181,893
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Capital assets               122,445     170,334     182,014     474,793
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Goodwill                       2,926     177,739           -     180,665
-------------------------------------------------------------------------
-------------------------------------------------------------------------


                                  Three months ended October 31, 2004
                           ----------------------------------------------
                              Canada         USA      Europe       Total
                                   $           $           $           $
-------------------------------------------------------------------------
Revenues
Canada                         5,454         670         325       6,449
USA                           33,143      29,378       1,823      64,344
Europe                         7,278         511      41,849      49,638
Other geographic areas           963         146       1,281       2,390
-------------------------------------------------------------------------
Total revenues                46,838      30,705      45,278     122,821
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Capital assets               113,484      33,808     184,433     331,725
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Goodwill                       2,837           -           -       2,837
-------------------------------------------------------------------------
-------------------------------------------------------------------------


                                 Twelve months ended October 31, 2005
                           ----------------------------------------------
                              Canada         USA      Europe       Total
                                   $           $           $           $
-------------------------------------------------------------------------
Revenues
Canada                        32,066       1,294       1,611      34,971
USA                          161,645     253,996       9,765     425,406
Europe                        39,883         715     190,980     231,578
Other geographic areas         3,548         387       2,428       6,363
-------------------------------------------------------------------------
Total revenues               237,142     256,392     204,784     698,318
-------------------------------------------------------------------------
-------------------------------------------------------------------------


                                 Twelve months ended October 31, 2004
                           ----------------------------------------------
                              Canada         USA      Europe       Total
                                   $           $           $           $
-------------------------------------------------------------------------
Revenues
Canada                        25,169       2,081         622      27,872
USA                          113,807     113,905       5,715     233,427
Europe                        34,761       2,507     165,131     202,399
Other geographic areas         2,936         516       3,109       6,561
-------------------------------------------------------------------------
Total revenues               176,673     119,009     174,577     470,259
-------------------------------------------------------------------------
-------------------------------------------------------------------------

Revenue is attributed to countries based on the location of the client's
billing address and capital assets and goodwill are based in the country
in which they are located.

Revenue information by service activity is as follows:

                                           Three months ended October 31,
                                          -------------------------------
                                               2005            2004
                                                  $               $
-------------------------------------------------------------------------
Commercial manufacturing - prescription     127,696   70%    76,454   62%
Commercial manufacturing - over-the-counter  27,675   15%    27,647   23%
Development services                         26,522   15%    18,720   15%
-------------------------------------------------------------------------
                                            181,893  100%   122,821  100%
-------------------------------------------------------------------------
-------------------------------------------------------------------------


                                          Twelve months ended October 31,
                                          -------------------------------
                                               2005            2004
                                                  $               $
-------------------------------------------------------------------------
Commercial manufacturing - prescription     498,113   71%   302,315   64%
Commercial manufacturing - over-the-counter 109,153   16%   102,165   22%
Development services                         91,052   13%    65,779   14%
-------------------------------------------------------------------------
                                            698,318  100%   470,259  100%
-------------------------------------------------------------------------
-------------------------------------------------------------------------

7.  Stock-based compensation

The Company has an incentive stock option plan. Persons eligible to
participate in the plan are directors, officers, and key employees of
Patheon and its subsidiaries or any other person engaged to provide
ongoing management or consulting services to Patheon. The plan provides
that the maximum number of shares that may be issued under the plan is
7.5% of the issued and outstanding common shares of the Company at any
point in time. At October 31, 2005, the total number of common shares
listed on the Toronto Stock Exchange (the "TSX") as available for
issuance under the plan was 6,963,427, of which 3,886,840 were reserved
for options granted and outstanding under the plan. The exercise price of
common shares subject to an option is determined at the time of grant and
the price cannot be less than the weighted average market price of the
common shares of Patheon on the TSX during the two trading days
immediately preceding the grant date. Options generally expire 10 years
after the grant date and are also subject to early expiry in the event of
death, resignation, dismissal or retirement of an optionee. Options
generally vest over three years, one-third on each of the first, second
and third anniversary of the grant date.

Stock options granted prior to November 1, 2003 are accounted for using
the intrinsic value method, which does not give rise to compensation
expense. Had these stock options been accounted for at fair value, the
impact on pro-forma net earnings and earnings per share would have been:

                              Three months ended     Twelve months ended
                                      October 31,             October 31,
                                2005        2004        2005        2004
                           ----------------------------------------------
                                   $           $           $           $
                           ----------------------------------------------
Net earnings as reported       8,379       2,997      21,621      10,678
Pro-forma adjustments for the
 fair value of stock options
 granted prior to November 1,
 2003                             27         (83)        (98)       (869)
                           ----------------------------------------------

Pro-forma net earnings         8,406       2,914      21,523       9,809
                           ----------------------------------------------
                           ----------------------------------------------

Pro-forma earnings per share:
  Basic                          9.3         5.6        24.8        19.0
                               cents       cents       cents       cents
  Diluted                        9.3         5.6        24.7        18.9
                               cents       cents       cents       cents


The fair value of stock options is estimated at the date of the grant.
The weighted average fair value of the 15,000 options granted for the
three months ended October 31, 2005 was $3.04. The weighted average fair
value of stock options granted for the twelve months ended October 31,
2005 was $3.01. The weighted average fair value of stock options granted
for the comparable twelve-month period in 2004 was $3.94. For the three
months ended October 31, 2005, 50,269 options were forfeited. The fair
value of stock options is estimated at the date of grant using the
Black-Scholes option pricing model with the following assumptions:

Risk free interest rate                               3.5%
Expected volatility                                   46%
Expected weighted average life of the options         5 years
Expected dividend yield                               0%

8.  Other information

Cumulative translation adjustment

The cumulative translation adjustment amount will be impacted by
fluctuations in the value of the U.S. dollar relative to the Canadian
dollar, the euro and the British sterling.

Unrealized translation adjustments, which arise on the translation to
U.S. dollars of the Company's assets and liabilities, resulted in a net
unrealized currency translation gain of $15,973,000 for the three months
ended October 31, 2005 (2004 - unrealized currency translation gain of
$11,017,000). For the twelve months ended October 31, 2005, the
unrealized currency translation gain is $13,664,000 (2004 - unrealized
currency translation gain of $15,402,000).

The net unrealized gain in the quarter of $15,973,000 is attributable to
the weakening of the U.S. dollar against the Canadian dollar and the
euro, as measured at October 31, 2005 and July 31, 2005, offset in part
by a strengthening of the U.S. dollar against the British sterling. On a
year-to-date basis, the net unrealized gain of $13,664,000 is
attributable to the weakening of the U.S. dollar against the Canadian
dollar, the euro and the British sterling, as measured at October 31,
2005 and October 31, 2004.

Foreign exchange

During the three months ended October 31, 2005, the foreign exchange loss
was $141,000 (2004 loss - $614,000). For the twelve months ended
October 31, 2005, the foreign exchange gain was $2,603,000 (2004 gain -
$24,000).

9.  Financial instruments

The Company utilizes financial instruments to manage the risk associated
with fluctuations in foreign exchange rates. The Company has entered into
foreign exchange expandable forward contracts with an aggregate amount of
between US$12,000,000 and US$18,000,000 as at October 31, 2005. These
contracts mature at the latest on December 31, 2005 at exchange rates
varying between 1.1850 and 1.2360 Canadian. The Company formally
documents all relationships between hedging instruments and hedged items,
as well as its risk management objective and strategy for undertaking
various hedge transactions. The mark-to-market value of these financial
instruments as at October 31, 2005 was an unrealized gain of US$220,000.

10. Long-term debt

On December 23, 2004, the Company completed a financing agreement for a
new $169,000,000 committed facility, comprising a three-year revolving
credit facility of up to $55,000,000 and a 12-month bridge facility of
$114,000,000. This bridge facility is intended to be refinanced by a term
loan within 12 months of the completion date. At the signing of the
financing agreement, $116,000,000 was drawn under these facilities in
partial payment of the cash portion of the purchase price of MOVA and
related transaction costs, and to refinance substantially all of the
Company's existing North American debt of approximately $63,000,000. At
October 31, 2005, the amount drawn under this bridge facility was reduced
to $81,500,000. Until the bridge facility is refinanced, the amount
outstanding is shown as a current liability. If the refinancing takes
place, the amount outstanding that is shown as a current liability is
anticipated to be reduced by approximately $80,000,000 with long-term
debt increased by the same amount.

Certain of the loan agreements which were assumed by the Company on
closing of the acquisition of MOVA Pharmaceutical Corporation require
MOVA to maintain certain financial covenants, as measured quarterly on a
calendar-year basis. As of December 31, 2004 and September 30, 2005,
MOVA's compliance reporting dates, MOVA was not in compliance with
certain of the financial covenants. The lending institutions have waived
their rights under the terms of the loan agreements for the non-
compliance of these covenants for a period of time up to November 1, 2006
and any cross-default provisions of the $169,000,000 credit facility,
referred to above, have also been remedied. Therefore, no change has been
made to the classification of long-term debt as presented in the
accompanying balance sheet.

11. Amortization and write-off of deferred financing costs

Amortization of deferred financing costs in the twelve months ended
October 31, 2005 was $4.8 million. No amounts were recorded for the same
period in the prior year. The write-off of $2.0 million relates to the
write-off of deferred financing costs recorded in the first quarter of
2005 and is of a non-recurring nature. No further amounts of a non-
recurring nature were recorded in subsequent quarters of 2005.

12. Deferred revenues

During the third quarter 2005, the Company entered into a Letter of
Intent with a client for the manufacturing of a lyophilized,
cephalosporin product at its Swindon site. In accordance with the terms
of the Letter of Intent, the client contributed $8.3 million
(euro 7.0 million) in the third quarter towards the capital cost of a new
cGMP plant at the Swindon site to accommodate the manufacturing of the
new client volumes. The contribution by the client has been recorded as
deferred revenues and will be recognized as income over the term of the
manufacturing services agreement, commencing in the 2007 fiscal year
through 2010.

13. Repositioning expenses

For the three months and twelve months ended October 31, 2004, the
Company recorded expenses related to the repositioning plan for its U.K.
operations designed to reduce operating losses. No amount was recorded
for the three months and twelve months ended October 31, 2005, as the
repositioning plan was completed by October 31, 2004.

14. Gain on sale of land

During the fourth quarter 2005, the Company disposed of a parcel of land
at its Bourgoin-Jallieu site in France. The sale closed October 17, 2005.
The proceeds received on the sale were $4.7 million and the gain
attributed on the sale was $4.6 million.

15. Subsequent event

On November 3, 2005, the Company announced that it is proceeding to put
in place new credit facilities in the aggregate amount of $290 million to
refinance existing debt of Patheon Inc. and its U.S. subsidiaries,
including its subsidiaries in Puerto Rico. The new facilities will
replace (i) existing credit facilities that are available to the
Company's North American operations including those that were established
at the time of acquisition of MOVA Pharmaceutical Corporation in December
2004, and (ii) debt of MOVA Pharmaceutical Corporation and its affiliates
in Puerto Rico that was assumed at the time of acquisition by Patheon.
The new credit facilities will comprise a revolving facility in the
amount of $75 million and two term loans in the aggregate amount of
$215 million. The term loans will consist of a five-year term loan in the
amount $65 million and a six-year term loan in the amount of
$150 million. The new facilities will be secured by the North American
assets of Patheon and its subsidiaries, including those of Puerto Rico.
The Company has engaged Royal Bank of Canada and RBC Capital Markets as
Lead Arranger to syndicate these new credit facilities to a group of
financial institutions in Canada and the United States. The refinancing
is expected to close in December 2005.

16. Comparative amounts

Certain of the comparative amounts have been reclassified to conform to
the current year presentation.


                            Patheon Inc.
     Management's Discussion and Analysis of Financial Condition
                      and Results of Operations

The following is a discussion of financial condition and results of
operations of Patheon Inc. ("Patheon" or "the Company") for the three-month
and twelve-month periods ended October 31, 2005 and 2004 and should be read in
conjunction with the Company's consolidated financial statements and related
notes contained in this interim report. This MD&A is dated as of December 13,
2005.
The purpose of this 2005 fourth quarter report is to provide an update to
the information contained in the Management's Discussion and Analysis (MD&A)
section of Patheon's 2004 Annual Report, which contains a more comprehensive
discussion of Patheon's strategy, capabilities to deliver results, risks and
key performance indicators. Management assumes that the reader of this
document has access to the MD&A section of Patheon's 2004 Annual Report, the
first report for which the Company adopted the latest MD&A reporting
requirements. This document and other information can be downloaded in
portable document format (PDF) from the Company's web site at www.patheon.com
or from the SEDAR web site for Canadian regulatory filings at www.sedar.com.
To request a printed copy, the reader may also contact Patheon's transfer
agent, Computershare Trust Company of Canada, at 1-800-564-6253 or via email
at service(at)computershare.com, or Patheon at www.patheon.com.

Use of Non-GAAP Financial Measures

Except as otherwise indicated, references in this MD&A to "EBITDA" are to
earnings before depreciation and amortization, interest, gain on sale of land
and income taxes. Free cash flow is defined as cash provided by operating
activities in excess of additions to capital assets in the period. "EBITDA
margin" is EBITDA divided by revenues. EBITDA and EBITDA margin are measures
of earnings or earnings margin not recognized by generally accepted accounting
principles in Canada ("Canadian GAAP"). Free cash flow is a measure of cash
flows not recognized by generally accepted accounting principles in Canada.
Since each of these measures is a non-GAAP measure that does not have a
standardized meaning, it may not be comparable to similar measures presented
by other issuers. Prospective investors are cautioned that these, and other
non-GAAP measures should not be construed as alternatives to net income
determined in accordance with Canadian GAAP as indicators of performance or to
cash flows from operating, investing and financing activities as measures of
liquidity and cash flows. The Company has included these measures because it
believes that this information is used by certain investors to assess
financial performance.

Overview of Patheon

Patheon is focused exclusively on providing commercial manufacturing and
pharmaceutical development services to pharmaceutical companies, biotechnology
companies and specialty pharmaceutical companies located primarily in North
America, Europe and Japan. Patheon serves its international clientele from its
operating facilities in North America and Europe.
Patheon's commercial manufacturing activities relate primarily to
prescription ("Rx") and over-the-counter ("OTC") products in solid, semi-solid
and liquid dosage forms and the manufacture of Rx products in sterile dosage
forms. Conventional dosage forms include compressed tablets, hard-shell
gelatin capsules, powders, ointments, creams, gels, syrups, suspensions,
solutions and suppositories. Sterile dosage forms include aseptically filled
liquids or terminally sterilized liquids filled in ampoules, vials, bottles or
pre-filled syringes. Sterile lyophilized products are also manufactured in
both vials and ampoules.
Patheon provides manufacturing services for a broad range of products in
many dosage forms and packaging formats in accordance with client
specifications. Depending on the particular client, Patheon may be responsible
for most or all aspects of the manufacturing and packaging process, from
sourcing raw materials and packaging components to delivering the finished
product in consumer-ready form to the client. Typically, Patheon's clients
supply the active pharmaceutical ingredients ("API") used in the production
process.
The pharmaceutical development services ("PDS") provided by Patheon
include most of the pharmaceutical development services typically required by
companies conducting clinical trials and preparing for full-scale commercial
production of a new drug.
At October 31, 2005, there were a total of 147 client projects in the
Patheon's PDS pipeline, including six drug candidates at the New Drug
Application ("NDA") stage, four of which are in-line for approval as early as
fiscal 2006. During the twelve months ended October 31, 2005, the Company's
PDS business had 31% growth in the number of projects from clients, who had
five NDA approvals during the year, including one subsequent to year end.

Vision and Strategy

Patheon's vision is to be the pre-eminent provider of pharmaceutical
manufacturing and development services across several dosage forms (solid,
semi-solid, liquid, powder and sterile/injectable). To achieve its goal,
Patheon has focused on being the preferred manufacturing and pharmaceutical
development services partner to the pharmaceutical industry. The Company
intends to use its position as a comprehensive provider of commercial
manufacturing services to establish and maintain long-term relationships with
clients on a global basis.

Key Performance Drivers

In Patheon's 2004 Annual Report, several key performance drivers were
identified for the Company: (i) increasing the percentage of overall revenues
derived from higher-margin Rx commercial manufacturing and pharmaceutical
development services; (ii) improving capacity utilization at the Company's
sites, which have a largely fixed-cost base in the short term; and (iii)
mitigating the impact of changes in the foreign exchange trading relationship
between the Canadian and U.S. dollar, since the Company's contracts in North
America are primarily in U.S. dollars, but the operating expenses of its six
Canadian sites are primarily in Canadian dollars. An update on our interim
performance relating to these key measures is provided in the section below
entitled "Results of Operations".

Acquisition of MOVA in the first quarter of 2005

On December 23, 2004, the Company completed the acquisition of MOVA
Pharmaceutical Corporation and MOVA Investments, Inc. (collectively "MOVA"), a
leading U.S. prescription pharmaceutical contract manufacturer located in
Puerto Rico, U.S.A.
The purchase price for the shares of MOVA was based on an enterprise
value for MOVA at closing of $350,000,000. The Company issued 12,684,866
common shares to the shareholders of MOVA in satisfaction of $81,500,000 of
the purchase price. The Company assumed approximately $133,300,000 in debt and
related costs, and paid $135,200,000 in cash at closing.
The agreement also provided for two earn-out arrangements relating to
MOVA's operating results for two specific periods. The maximum amounts for the
first and second earn-outs were $65 million and $26 million, respectively. The
Company placed into escrow $87.8 million to support potential payments under
the earn-out arrangements. An agreement was reached with the former MOVA
shareholders to pay the full amount of the first earn-out arrangement and
$65 million was disbursed from escrow on June 23, 2005. It was determined that
no amount was payable under the second earn-out and the remaining funds held
in escrow were released to the Company and applied to reduce debt.
The acquisition has been accounted for using the purchase method and the
accompanying consolidated financial statements include the results of
operations from the date of purchase. The purchase price was allocated in the
accounts based on the fair value of the assets acquired as follows:

                                                               ----------
                                                                       $
                                                               ----------
Current assets                                                    62,176
Capital assets                                                   128,050
Other long term assets                                             1,719
Intangible assets                                                116,274
Goodwill                                                         170,161
Current liabilities                                              (34,430)
Deferred revenues                                                 (7,096)
Future tax liabilities                                            (3,402)
                                                               ----------
Net assets acquired before assumed debt                          433,452
Less: debt assumed                                              (133,333)
                                                               ----------
Net assets acquired                                              300,119
                                                               ----------
                                                               ----------

Intangible assets, which represent the value assigned to client
contracts, are being amortized on a straight-line basis over nine years.

The purchase price consideration was as follows:

                                                               ----------
                                                                       $
                                                               ----------
Cash consideration                                               208,489
Transaction costs                                                  3,334
                                                               ----------
Total cash consideration                                         211,823
Value of 12,684,866 common shares issued to shareholders
 of MOVA                                                          88,296
                                                               ----------
Total consideration                                              300,119
                                                               ----------
                                                               ----------

In accordance with generally accepted accounting principles, the value of
the 12,684,866 common shares was determined based on the average market price
of the Company's common shares for the two trading days prior to the
announcement of the transaction and the two trading days following the
announcement.

Results of Operations

Three Months Ended October 31, 2005 Compared with Three Months Ended
October 31, 2004

The results for the three-month period ended October 31, 2005 include the
operations of MOVA for three months, while the results of the comparative
period do not.

Revenues by Geographic Region and Service Activity

                          Three months ended         Twelve months ended
                                  October 31,                 October 31,
                                         %                           %
                       2005      2004 change       2005      2004 change
                   ------------------------------------------------------
North America
-------------
  Commercial
   Manufacturing
    Prescription     78,885    35,617    121%   313,078   141,539    121%
    Over-the-counter 27,420    27,265      1%   107,337   100,613      7%
                   ------------------------------------------------------
                    106,305    62,882     69%   420,415   242,152     74%
  Development
   Services          21,268    14,661     45%    73,119    53,530     37%
                   ------------------------------------------------------
                    127,573    77,543     65%   493,534   295,682     67%
                   ------------------------------------------------------
Europe
------
  Commercial
   Manufacturing
    Prescription     48,811    40,837     20%   185,035   160,776     15%
    Over-the-counter    255       382    -33%     1,816     1,552     17%
                   ------------------------------------------------------
                     49,066    41,219     19%   186,851   162,328     15%
  Development
   Services           5,254     4,059     29%    17,933    12,249     46%
                   ------------------------------------------------------
                     54,320    45,278     20%   204,784   174,577     17%
                   ------------------------------------------------------
TOTAL
-----
  Commercial
   Manufacturing
    Prescription    127,696    76,454     67%   498,113   302,315     65%
    Over-the-counter 27,675    27,647      0%   109,153   102,165      7%
                   ------------------------------------------------------
                    155,371   104,101     49%   607,266   404,480     50%
  Development
   Services          26,522    18,720     42%    91,052    65,779     38%
                   ------------------------------------------------------
CONSOLIDATED
 REVENUES           181,893   122,821     48%   698,318   470,259     48%
                   ------------------------------------------------------
                   ------------------------------------------------------

Revenues

Consolidated revenues for the three-month period ended October 31, 2005
increased 48% or $59.1 million to $181.9 million from $122.8 million in the
same period in 2004. In the fourth quarter, growth came from prescription (Rx)
manufacturing and pharmaceutical development services (PDS) in both North
America and Europe. On a consolidated basis, commercial manufacturing revenues
grew 49%, with Rx manufacturing up 67%, while revenues from over-the-counter
(OTC) manufacturing were comparable to those in the fourth quarter of 2004.
PDS revenues were up 42% compared with the same period in 2004.
Internal growth, or new business from existing sites, was $18.2 million,
or 15%, in the fourth quarter of 2005, 12% in North America and 20% in Europe.
Internal growth in North America was attributable principally to Rx
manufacturing and PDS services, which were up $4.6 million or 13%, and
$4.4 million or 30%, respectively, compared with the same period in 2004. In
Europe, growth was also attributable principally to Rx manufacturing and PDS
services, which were up $8.0 million, or 20% and $1.2 million, or 29%,
respectively, compared with the same period in 2004. On a constant exchange
rate (CER) basis to prior year, internal growth in Europe was 22% in the
fourth quarter of 2005.
Prescription manufacturing and development services represented 85% of
revenues, compared with 77% for the comparable period in 2004, a result of
internal growth in Rx and PDS services and strategic growth from MOVA, where
commercial services are all Rx. OTC revenues were relatively unchanged in the
fourth quarter, as compared with the same period a year ago, a result of
steady OTC volumes in North America. PDS revenues increased 42% in the fourth
quarter, reflecting continued momentum at PDS sites in North America and
Europe. PDS fourth quarter revenue growth was 45% in North America and 29% in
Europe, as compared with the same period a year ago.
Geographically, North American revenue growth was $50.0 million or 65%
over the same period in the prior year. Of the revenue increase, $40.9 million
was strategic growth related to the acquisition of the MOVA operations. MOVA
revenues in the third and fourth quarters of 2005 were impacted principally by
a decision taken by CEPH International Corporation to voluntarily suspend
production of an oral powder for suspension product while it resolved issues
identified in a Warning Letter from the U.S. Food and Drug Administration,
(FDA). These challenges resulted in lower capacity utilization at MOVA in the
third and fourth quarters. Net internal growth in North America was
$9.1 million, reflecting growth in both Rx and PDS services. In North America,
the Whitby site faced challenges as a result of significantly lower than
anticipated volumes in connection with a new product launch as well as
capacity constraints related to increased demand for certain OTC products. In
North America, Rx revenues were driven by new product launches at the Toronto
high-potency site. North American PDS revenues continued the growth trend
experienced through 2005 with stronger momentum in the fourth quarter.
Revenues from sites in North America represented 70% of total revenues in
the fourth quarter of 2005, compared with 63% in the same period in 2004. This
reflects the inclusion of revenues related to the MOVA operations and growth
in Rx and PDS service activities from the other operations in North America.
In Europe, revenues for the fourth quarter of 2005 were 20% higher than
the same period of 2004. European currencies had nominal changes against the
U.S. dollar in the fourth quarter of fiscal 2005 compared with the prior year.
The euro weakened approximately 1% and the British sterling weakened
approximately 1% against the U.S. dollar, decreasing reported revenues by
approximately $0.9 million. On a constant exchange rate (CER) basis, net
earnings in the fourth quarter of 2005 would have been 0.3 cents higher. The
year-over-year increase in revenues is due to improved performance at the
sites in Monza and Ferentino, Italy, Swindon, U.K. and growth in the PDS
business.

Operating Expenses

Operating expenses comprise processing costs (principally materials,
employee and other site-related costs), marketing, sales, service, corporate
support and administrative expenses. In the fourth quarter of 2005, operating
expenses were $155.7 million, compared with $109.3 million in the same period
a year ago, an increase of 42%. Operating expenses as a percentage of revenues
were 85.6%, compared with 89.0% in the prior year. Excluding the impact of the
MOVA operations, operating expenses as a percentage of revenues were 84.8%
compared with 89.0% in the same period a year ago. Excluding the impact of
repositioning expenses, operating expenses in the fourth quarter of 2004 were
$107.1 million or 87.2% as a percentage of revenues.

EBITDA and EBITDA Margin

On a consolidated basis in the fourth quarter of 2005, EBITDA,
representing earnings before depreciation and amortization, interest, gain on
sale of land and income taxes was $26.2 million, an increase of $12.7 million,
or 94%, from the comparable period in 2004. As a percentage of consolidated
revenues, the EBITDA margin was 14.4% in the three-month period, compared with
11.0% in the same period a year ago. The comparable EBITDA margin in the prior
year excluding the U.K. repositioning costs was 12.8%. While in the first half
of 2005, MOVA had higher EBITDA margins than other operations in the Company's
network, in the third quarter, MOVA's EBITDA margins were comparable with the
other operations and in the fourth quarter, they were lower. MOVA EBITDA
margins were lower in the second half of 2005 principally due to reduced
capacity utilization. The relatively strong EBITDA margins for the other sites
in the Company's network were largely due to higher volumes at the Italian
sites, related to the continuing strong growth of the lyophilization business,
significantly improved financial performance at the Swindon, U.K. operations
and new product launches and volume increases at the Toronto high-potency
site. Year-over-year growth in EBITDA margins for the fourth quarter was also
favourably impacted by the continued growth in PDS revenues in both North
America and Europe.

Depreciation Expense

Depreciation expense was $7.8 million in the fourth quarter of 2005,
compared with $6.0 million in the fourth quarter of 2004, an increase of
$1.8 million, or 31%. Of the increase, $0.7 million is attributable to
additional amounts relating to depreciation of the MOVA assets, $0.3 million
is attributable to the effect of translation to U.S. dollars of depreciation
related to Canadian and European sites, and the remainder principally related
to the capital programs at the Italian sites and capital programs in North
America, principally at the Toronto, Canada, and Cincinnati, U.S.A. sites.
Depreciation expense in the fourth quarter relating to MOVA operations include
adjustments made on finalization of fixed assets valuations for MOVA in the
fourth quarter of 2005. Depreciation expense also includes the amortization of
deferred pre-operating costs, although there was no significant change on a
year-over-year basis.

Amortization of Deferred Financing Costs

Amortization of deferred financing costs in the fourth quarter of 2005
was $1.3 million, comparable to the amount recorded in the previous quarter.
No amounts were recorded for the same period in the prior year. There were no
amounts of a non-recurring nature in the fourth quarter.

Amortization of Intangible Assets

The amortization of intangible assets relates to the acquisition of the
MOVA operations. Intangible assets, which represent the value assigned to
client contracts, are being amortized on a straight-line basis over nine
years. The quarterly amortization amount on this basis in the fourth quarter
was approximately $3.4 million, compared with $3.2 million in the third
quarter of 2005.

Interest Expense

Interest expense for the fourth quarter of 2005 was $4.7 million,
comparable to the third quarter of 2005, but is an increase of $2.9 million
over the same period in the prior year. Approximately $2.8 million of the  
year-over-year increase is related to new debt associated with the acquisition
of the MOVA operations in December 2004.

Gain on Sale of Land

Fourth quarter results include an amount, pre-tax, of $4.6 million
relating to a gain on sale of land in France that the Company sold in the
fourth quarter. The sale closed October 17, 2005 and related to land the
Company owned adjacent to its principal operations and which was not
considered to be integral to the long-term operations or expansion plans for
the site. No amounts were recorded for the comparable period in 2004.

Earnings Before Income Taxes

Earnings before income taxes, increased 137% to $13.6 million in the
fourth quarter of 2005, from $5.7 million in the same period a year ago. The
increase is attributed to a one-time pre-tax gain on the sale of land in
France of $4.6 million, and increased volumes from certain North American
operations and the U.K. operations as compared with the same period in the
prior year. This was offset by increased depreciation and amortization charges
in the fourth quarter of 2005, related to the MOVA acquisition, and increased
depreciation and interest expense in North America and Europe related to
ongoing capital and growth support programs.

Income Taxes

The effective income tax rate in the fourth quarter of 2005 was 38.3%
versus 47.8% for the same period a year ago and 42.7% before repositioning
expenses for the fourth quarter of 2004. The effective rate in the prior year
reflected the impact of losses incurred in the U.K. which were recorded at
30%, a rate which is lower than other Patheon operations in 2004. The
effective tax rate of 38.3% in the fourth quarter of 2005 reflects a reduction
arising from the improved operating performance in the U.K., offset somewhat
by the inclusion of the MOVA operations, currently at the lowest tax rate in
the Patheon group.

Net Earnings and Earnings Per Share

Net earnings for the fourth quarter of 2005 were $8.4 million, compared
with $3.0 million in the same period last year, an increase of $5.4 million,
or 180%. Earnings per share were 9.3 cents compared with 5.8 cents a year
earlier, an increase of 60%. Net earnings in the fourth quarter of 2005
include the gain on sale of land in France of $3.0 million after tax. Earnings
per share relating to this sale were approximately 3.5 cents in the fourth
quarter of 2005. Earnings per share in the fourth quarter of 2005 were
negatively impacted by lower capacity utilization at the MOVA operations. Net
earnings before repositioning expenses in the fourth quarter of 2004 were
$4.6 million, or 8.9 cents per share based on a lower number of average shares
outstanding for the period.
The average number of shares outstanding during the three-month period
increased 80% determined on both the basic and diluted bases. The increase is
the result of shares issued in connection with the acquisition of MOVA, as
described in notes 3 and 4 of the financial statements herein.
Diluted earnings per share were 9.3 cents compared with 5.8 cents in the
fourth quarter of 2004, an increase of 60%. Dilution arises solely from
options issued under the Company's stock option plan.

Twelve months Ended October 31, 2005 Compared with Twelve months Ended
October 31, 2005

The results for the twelve-month period ended October 31, 2005 include
the operations of MOVA since the date of acquisition on December 23, 2004,
while the results of the comparative period do not.

Revenues

Consolidated revenues for the twelve-month period ended October 31, 2005
increased 48% or $228.1 million to $698.3 million from the same period in
2004. In the twelve-month period, all service activities contributed to the
growth. On a consolidated basis, commercial manufacturing revenues grew 50%,
with prescription (Rx) manufacturing up 65% and over-the-counter (OTC)
manufacturing up 7%, while pharmaceutical development services (PDS) revenues
were up 38%.
Internal growth, or new business from existing sites, was $78.8 million,
or 17%, in the twelve-month period of 2005, 16% in North America and 17% in
Europe. Strategic growth in the twelve-month period of 2005 was
$149.3 million, related to MOVA. All service activities contributed to the
strong internal growth in North America. In Europe, growth was attributable
principally to Rx manufacturing and PDS services, which were up $24.3 million,
or 15% and $5.7 million, or 46%, respectively, compared with the same period
in 2004.
Prescription manufacturing and development services represented 84% of
revenues, compared with 78% for the comparable period in 2004, a result of
internal growth in Rx and PDS services and strategic growth from MOVA, where
commercial services are all Rx.
OTC revenues increased 7% in fiscal 2005, as compared with the same
period a year ago. While the Company reported double-digit growth in OTC
revenues in North America in the first and second quarters of 2005, OTC
revenues declined 3% in the third quarter of 2005 and were comparable in the
fourth quarter, as compared with the same periods a year ago. This segment of
the pharmaceutical market is highly competitive, price-sensitive and subject
to volatility in consumer demand.
PDS revenues increased 38% in the twelve-month period, reflecting
continuing momentum at PDS sites in North America and Europe. PDS twelve-month
revenue growth was 37% in North America and 46% in Europe, as compared with
the same period a year ago. Growth in PDS revenues reflects the continuing
favourable financing environment for drug development as well as the Company's
enhanced reputation in the marketplace to provide formulation development
services and commercialization of newly approved products for its clients.
Geographically, North American revenue growth was $197.9 million or 67%
over the same period in the prior year. Of the revenue increase,
$149.3 million was strategic growth related to the acquisition of the MOVA
operations. Net internal growth was $48.7 million, or 16%, reflecting strong
growth in Rx manufacturing services, principally from the Toronto high-potency
operations. In North America, the Whitby site faced challenges as a result of
significantly lower than anticipated volumes in connection with a new product
launch as well as capacity constraints related to increased demand for certain
OTC products. In Europe, significant year-over-year increases in Rx internal
growth revenues came principally from the Italian operations, reflecting
continuing strong growth in the commercial business and the improved
performance of the Swindon, U.K. operations. Strong growth in PDS was reported
at the Canadian, European and Cincinnati sites.
Revenues from sites in North America represented 71% of total revenues in
fiscal 2005, compared with 63% in fiscal 2004. This reflects the inclusion of
revenues related to the MOVA operations and growth in all service activities
from the other operations in North America.
In Europe, revenues for the twelve-month period were 17% higher than the
same period of 2004. European currencies remained strong against the U.S.
dollar in the twelve months of fiscal 2005 compared with the prior year. The
euro strengthened approximately 4% and the British sterling strengthened
approximately 2% against the U.S. dollar, increasing reported revenues by
approximately $5.2 million. Had European currencies remained constant to the
rates of the prior year, European revenues would have been 14% higher than the
same period in 2004. Net earnings for the twelve months of 2005 would have
been higher by approximately 0.7 cents per share, on a constant exchange rate
(CER) basis.

Operating Expenses

Operating expenses comprise processing costs (principally materials,
employee and other site-related costs), marketing, sales, service, corporate
support and administrative expenses. In the twelve-month period ended
October 31, 2005, operating expenses were $600.4 million, compared with
$422.2 million in the same period a year ago, an increase of 42%. Operating
expenses as a percentage of revenues were 86.0%, compared with 89.8% in the
prior year. Excluding the impact of repositioning expenses, operating expenses
as a percentage of revenues were 88.8% in fiscal 2004. Excluding the impact of
the MOVA operations, operating expenses as a percentage of revenues were 87.5%
in fiscal 2005.

EBITDA and EBITDA Margin

On a consolidated basis in fiscal 2005, EBITDA, representing earnings
before depreciation and amortization, interest, gain on sale of land and
income taxes was $98.0 million, an increase of $49.9 million, or 104%, from
the comparable period in 2004. As a percentage of consolidated revenues,
EBITDA was 14.0% in the twelve-month period, compared with 10.2% in 2004.
Excluding the impact of repositioning expenses, EBITDA as a percentage of
consolidated revenues was 11.2% in fiscal 2004. The growth in EBITDA is
attributed principally to the contribution of the MOVA business and increases
in Rx and PDS services in North America and Europe. As expected, the Swindon
U.K. operation was EBITDA positive in fiscal 2005.

Depreciation Expense

Depreciation expense was $33.4 million in fiscal 2005, compared with
$22.8 million in the same period of 2004, an increase of $10.6 million, or
47%. Of the increase, $7.0 million is attributable to additional amounts
relating to depreciation of the MOVA assets, $1.6 million is attributable to
the effect of translation to U.S. dollars of depreciation related to Canadian
and European sites, and the remainder principally related to the capital
programs at the Italian sites and capital programs in North America,
principally at the Toronto, Canada, and Cincinnati, U.S.A. sites. Depreciation
expense also includes the amortization of deferred pre-operating costs.

Amortization and write-off of Deferred Financing Costs

Amortization of deferred financing costs in the twelve months ended
October 31, 2005 was $4.8 million. No amounts were recorded for the same
period in the prior year. The write-off of $2.0 million relates to the   
write-off of deferred financing costs recorded in the first quarter of 2005
and is of a non-recurring nature. No further amounts of a non-recurring nature
were recorded in subsequent quarters of 2005.

Amortization of Intangible Assets

The amortization of intangible assets of $11.2 million in fiscal 2005
relates to the acquisition of the MOVA operations in December 2004. Intangible
assets, which represent the value assigned to client contracts, are being
amortized on a straight-line basis over nine years.

Interest Expense

Interest expense in 2005 was $16.4 million compared with $5.6 million in
fiscal 2004, an increase of $10.8 million. Approximately $9.3 million of the
year-over-year increase is related to new debt associated with the acquisition
of the MOVA operations in December 2004. The remainder of the year-over-year
increase is principally related to increased spending to finance the capital
programs in North America and Europe.

Earnings Before Income Taxes

Earnings before income taxes, increased 76% to $34.7 million in fiscal
2005, from $19.7 million in the same period a year ago. The increase is
attributed to the inclusion of the results of the MOVA operations, increased
volumes from certain North American operations and the European operations, as
compared with the same period in the prior year. This was offset by increased
depreciation and amortization charges, related to the MOVA acquisition, and
increased depreciation and interest expense in North America and Europe,
related to ongoing capital and growth support programs.

Income Taxes

The effective income tax rate for the twelve months ended October 31,
2005 was 37.7% versus 45.9% in the same period in 2004 and 43.0% before
repositioning expenses in 2004. The effective tax rate in the prior period was
significantly impacted by the losses incurred at the U.K. operations, which
were at 30%, a rate lower than the other Patheon operations in 2004. The lower
effective tax rate for the twelve-month period in 2005 reflects the positive
impact of the improved financial performance of the U.K. operations as well as
the inclusion of earnings from the MOVA operations as of December 23, 2004.
The effective tax rate for the MOVA operations in Puerto Rico, U.S.A. is
approximately 3%. As a result, the amounts of earnings from operations in
Puerto Rico, relative to earnings of the Company's earnings outside of Puerto
Rico, can significantly impact the consolidated effective tax rate.

Net Earnings and Earnings Per Share

Net earnings for the twelve months ended October 31, 2005 were
$21.6 million, compared with $10.7 million in fiscal 2004, an increase of
$10.9 million, or 102%. Basic earnings per share in fiscal 2005 were
24.9 cents compared with 20.7 cents in the same period of 2004, an increase of
20%. Excluding the impact of repositioning expenses, basic earnings per share
in the twelve months of 2004 were 26.7 cents. Year-to-date results were
impacted positively by improved operating performance, principally at the
Toronto high-potency site, the European operations and the year-over-year
growth in PDS. The MOVA operations were not accretive to earnings in the
twelve-month period ended October 31, 2005 as a result of issues with two key
products.
The average number of shares outstanding during the twelve-month period,
determined on the basic and diluted bases, increased 69% and 68% respectively.
The increase is the result of shares issued in connection with the acquisition
of MOVA as described in notes 3 and 4 of the financial statements herein.
Diluted earnings per share were 24.8 cents compared with 20.6 cents in
the twelve months ended October 31, 2004, an increase of 20%. Dilution arises
solely from options issued under the Company's stock option plan.

Seasonal Variability of Results

Typically, Patheon's manufacturing and PDS revenues are lower in the
first fiscal quarter. While commercial revenues in Europe followed this
pattern, this was not the case for the European PDS revenues or for North
American PDS and commercial volumes. This is principally attributable to
higher-than-anticipated commercial volumes at the Canadian sites related to
new business and product launches, and continuing strong demand for PDS
related to existing contracts in the first quarter. This trend continued in
the second, third and fourth quarters with the inclusion of full quarters of
MOVA operations, strong commercial demand in Europe and strong sequential
demand for PDS in North America and Europe.

Liquidity and Capital Resources

Summary of Cash Flows

The following table summarizes the Company's cash flows for the periods
indicated:

                              Three months ended     Twelve months ended
                                      October 31,             October 31,
                                2005        2004        2005        2004
                          ----------------------- -----------------------
                                   $           $           $           $
                          ----------------------- -----------------------

Net earnings                   8,379       2,997      21,621      10,678
Depreciation and
 amortization                 12,552       5,951      49,363      22,765
Write-off of deferred
 financing costs (note 11)         -           -       2,010           -
Future income taxes            1,971         729       2,642       2,384
Employee future benefits         244         881       1,639       2,688
Loss on sale of investment         -          33           -          33
Gain on sale of land
 (note 14)                    (4,587)          -      (4,587)          -
Equipment write-down
 (note 13)                         -         (79)          -         671
Stock-based compensation         319         445       1,528       1,373
Amortization of deferred
 revenues                       (280)          -        (898)          -
Other                             52           -         217           -
Working capital                5,674       9,658      (4,640)       (173)
                          ----------- ----------- ----------- -----------
Cash provided by operating
 activities                   24,324      20,615      68,895      40,419
Cash provided by (used in)
 financing activities         (7,776)      2,663     228,977      21,719
Cash used in investing
 activities                  (11,165)    (19,328)   (276,176)    (63,761)
Other                          1,139         260      (3,834)         79
                          ----------- ----------- ----------- -----------
Net increase (decrease) in
 cash and cash equivalents     6,522       4,210      17,862      (1,544)
                          ----------- ----------- ----------- -----------
                          ----------- ----------- ----------- -----------

Note reference is to the unaudited consolidated financial statements for
the three-month and twelve-month period ended October 31, 2005.

On a year-to-date consolidated basis, the free cash flow generated in
2005 was $12.1 million versus higher cash needs in fiscal 2004 to finance
working capital and capital spending programs. Free cash flow is defined as
cash provided by operating activities in excess of additions to capital assets
in the period. Free cash flow is a non-GAAP measure. Please refer to the
section describing the use of non-GAAP measures in this MD&A.
Generation of cash from working capital was $5.7 million in the fourth
quarter of 2005, compared with the requirement to fund working capital on a
year-to-date basis of $4.6 million in 2005. This was principally a result of
the phasing of manufacturing and related client billings and the impact of the
MOVA operations.

Cash Provided by Operating Activities

Cash provided by operating activities increased by $3.7 million to
$24.3 million in the fourth quarter of 2005, compared with the same period a
year ago. Of the increase, $7.7 million related to the year-over-year increase
in cash provided from operations, offset somewhat by an increase in working
capital requirements quarter-over-quarter.
For the twelve-month period, cash provided by operating activities
increased by $28.5 million to $68.9 million. The increase in cash provided
from operations of $32.9 million was offset somewhat by an increase in working
capital requirements of $4.4 million. The Company will continue its focus on
working capital management in 2006.

Cash Used in Investing Activities

Cash used in investing activities for the fourth quarter of 2005 was
$11.2 million, compared with a use of $19.3 million in the same period of
2004. The decrease is principally related to reductions in capital spending
programs at the Toronto site and Italian sites and the proceeds received on
the sale of land in France.
Cash used in investing activities for the twelve months ended October 31,
2005 was $276.2 million, compared with $63.8 million in 2004. The year-over-
year increase is principally related to the MOVA acquisition on December 23,
2004. A summary is as follows:

                              Three months ended      Twelve months ended
                                      October 31,             October 31,
                                2005        2004        2005        2004
                          ----------------------- -----------------------
                                   $           $           $           $
                          ----------------------- -----------------------

Additions to capital assets
  Sustaining                   6,734       3,191      16,062      11,232
  Project-related             11,177      16,492      40,730      51,372
                          ----------- ----------- ----------- -----------
Total additions to capital
 assets                       17,911      19,683      56,792      62,604
Acquisition of MOVA
 Pharmaceutical Corporation
 (note 3)                     (2,698)          -     211,823           -
Proceeds on sale of land
 (note 14)                    (4,748)          -      (4,748)          -
Proceeds on sale of
 investment                        -        (265)          -        (265)
Redemption of certificate
 of deposit                        -           -        (391)          -
Increase (decrease) in
 deferred pre-operating and
 financing costs                 700         (90)     12,700       1,422
                          ----------- ----------- ----------- -----------
Cash used in investing
 activities                   11,165      19,328     276,176      63,761
                          ----------- ----------- ----------- -----------
                          ----------- ----------- ----------- -----------

Note reference is to the unaudited consolidated financial statements for
the three-month and twelve-month period ended October 31, 2005.

Cash Provided by Financing Activities

The principal financing activity for the twelve months ended October 31,
2005 occurred in the first quarter of 2005, and was the completion of the
common share offering. Proceeds from the offering were $199.2 million, before
costs, and $190.3 million after costs. Proceeds were used to finance a portion
of the purchase price of MOVA of $350.0 million and to finance, in escrow,
approximately 90% of the maximum amount of $91.0 million potentially payable
under the earn-out agreements. The Company placed into escrow $87.8 million to
support potential payments under the earn-out arrangements. An agreement was
reached with the former MOVA shareholders to pay the full amount of the first
earn-out arrangement and $65 million was disbursed from escrow on June 23,
2005. It was determined that no amount was payable under the second earn-out
and the remaining funds held in escrow were released to the Company and
applied to reduce debt. A summary is as follows:

                              Three months ended      Twelve months ended
                                      October 31,             October 31,
                                2005        2004        2005        2004
                          ----------------------- -----------------------
                                   $           $           $           $
                          ----------------------- -----------------------

Increase (decrease) in bank
 indebtedness                  1,536       4,527      (6,195)      8,246
Increase in term loans        46,355      13,285     341,445      74,588
Repayment of long-term debt
 and other long-term
 liabilities                 (55,667)    (15,149)   (304,838)    (61,137)
Increase in deferred
 revenues (note 12)                -           -       8,271           -
Proceeds on issue of
 common shares before costs        -           -     199,241          22
Share issue costs                  -           -      (8,947)          -
                          ----------- ----------- ----------- -----------
Cash provided by (used in)
 financing activities         (7,776)      2,663     228,977      21,719
                          ----------- ----------- ----------- -----------
                          ----------- ----------- ----------- -----------

Note reference is to the unaudited consolidated financial statements for
the three-month and twelve-month period ended October 31, 2005.

Financing Arrangements and Ratios

At October 31, 2005, the Company's consolidated ratio of interest-bearing
long-term debt (including current portion) to shareholders' equity was 53.4%
compared with 57.8% at July 31, 2005 and 56.1% at October 31, 2004. At
October 31, 2005, the Company's consolidated ratio of interest-bearing debt
(including current portion and bank indebtedness) to shareholders' equity was
56.1%, compared with 60.3% at July 31, 2005 and 65.9% at the end of the 2004
fiscal year. The reduction was principally due to the release of funds held in
escrow which were applied against the bridge facility.
The Certificate of deposit of $4,824,000 and $3,615,000 of the amount
reported as cash and cash equivalents are restricted cash and are held in
support of certain debt agreements of MOVA.
Certain of the loan agreements which were assumed by the Company on
closing of the acquisition of MOVA Pharmaceutical Corporation require MOVA to
maintain certain financial covenants, as measured quarterly on a calendar-year
basis. As of December 31, 2004 and September 30, 2005, MOVA's compliance
reporting dates, MOVA was not in compliance with certain of the financial
covenants. The lending institutions have waived their rights under the terms
of the loan agreements for the non-compliance of these covenants for a period
of time up to November 1, 2006 and any cross-default provisions of the
$169,000,000 credit facility, referred to above, have also been remedied.
Therefore, no change has been made to the classification of long-term debt as
presented in the accompanying balance sheet.
On December 23, 2004, the Company completed a financing agreement for a
new $169,000,000 committed facility, comprising a three-year revolving credit
facility of up to $55,000,000 and a 12-month bridge facility of $114,000,000.
This bridge facility is intended to be refinanced by a term loan within 12
months of the completion date. At the signing of the financing agreement,
$116,000,000 was drawn under these facilities in partial payment of the cash
portion of the purchase price of MOVA and related transaction costs, and to
refinance substantially all of the Company's existing North American debt of
approximately $63,000,000. At October 31, 2005, the amount drawn under this
bridge facility was $81,500,000, comparable to July 31, 2005. Until the bridge
facility is refinanced, the amount outstanding is shown as a current
liability. If the refinancing takes place, the amount outstanding that is
shown as a current liability is anticipated to be reduced by approximately
$80,000,000 with long-term debt increased by the same amount.
With the acquisition of MOVA, the Company assumed $133.3 million of debt
secured by the assets of MOVA.
Subsequent to year end, on November 3, 2005, the Company announced that
it will be proceeding to put in place new credit facilities in the aggregate
amount of $290 million to refinance existing debt of Patheon Inc. and its U.S.
subsidiaries, including its subsidiaries in Puerto Rico. The new facilities
will replace (i) existing credit facilities that are available to the
Company's North American operations including those that were established at
the time of the acquisition of MOVA Pharmaceutical Corporation in December
2004, and (ii) debt of MOVA Pharmaceutical Corporation and its affiliates in
Puerto Rico that was assumed at the time of the acquisition by Patheon.
The new credit facilities will comprise a revolving facility in the
amount of $75 million and two term loans in the aggregate amount of
$215 million. The term loans will consist of a five-year term loan in the
amount of $65 million and a six-year term loan in the amount of $150 million.
The new facilities will be secured by the North American assets of Patheon and
its subsidiaries, including those in Puerto Rico.
The Company has engaged Royal Bank of Canada and RBC Capital Markets as
Lead Arranger to syndicate these new credit facilities to a group of financial
institutions in Canada and the United States. The refinancing is expected to
close in December 2005. In connection with the new facilities, deferred
financing charges and pre-payment penalties of approximately $7.6 million
related to the previous lending arrangements will be charged to earnings in
the first quarter of fiscal 2006. It is expected that future operations will
benefit from the lower lending costs under the new financing arrangements.

Adequacy of Financial Resources

The Company believes that its financial resources are sufficient to fund
projected capital expenditures and debt service requirements in the normal
course of business. The Company is in the process of refinancing the bridge
facility of $81.5 million, referred to above, to a term loan facility.

Critical Accounting Policies and Estimates

General

Patheon's significant accounting policies are described in Note 1 to the
2004 consolidated financial statements. The most critical of these policies
are those related to revenue recognition, goodwill, income taxes and employee
future benefits (Notes 1, 12 and 13 of the 2004 audited financial statements).
The preparation of the consolidated financial statements requires
management to make estimates and assumptions that affect the reported amounts
of assets, liabilities, revenues and expenses. These estimates and assumptions
are based upon management's historical experience and are believed by
management to be reasonable under the circumstances. Such estimates and
assumptions are evaluated on an ongoing basis and form the basis for making
judgments about the carrying values of assets and liabilities that are not
readily apparent from other sources. Actual results could differ significantly
from these estimates.
The Company's Critical Accounting Policies have been reviewed and
discussed with the Company's Audit Committee.

Revenue Recognition

The Company recognizes revenue for its commercial manufacturing and
pharmaceutical development services when services are completed in accordance
with specific agreements with its clients and all costs connected with
providing these services have been incurred, price is fixed or determinable
and collectibility is reasonably assured.
The Company does not receive any fees on signing of contracts. In the
case of pharmaceutical development services, revenue is recognized on the
achievement of specific milestones. In the case of commercial manufacturing
services, revenue is recognized when services are complete and the product has
met rigorous quality assurance testing.

Valuation of Goodwill

The Company evaluates goodwill for impairment at least annually. If the
carrying value of the reporting unit exceeds the reporting unit's fair value,
any excess represents an impairment loss.
The goodwill shown on the financial statements for the period ended
October 31, 2005 was $180.7 million and relates to the acquisition in 2000 of
the remaining shares of Global Pharm Inc., which now operates as Toronto York
Mills Operations, and from the acquisition of MOVA Pharmaceutical Corporation
on December 23, 2004. As at October 31, 2005, goodwill shown on the financial
statements relating to the MOVA acquisition was $177.8 million and goodwill
shown relating to Toronto York Mills acquisition was $2.9 million.

Income Taxes

In accordance with Canadian GAAP, the Company uses the liability method
of accounting for future income taxes and provides for future income taxes for
significant temporary timing differences.
Preparation of the consolidated financial statements requires an estimate
of income taxes in each of the jurisdictions in which the Company operates.
The process involves an estimate of the Company's current tax exposure and an
assessment of temporary differences resulting from differing treatment of
items such as depreciation and amortization for tax and accounting purposes.
These differences result in future tax assets and liabilities and are
reflected in the consolidated balance sheet.
Future tax assets of $21.4 million have been recorded at October 31,
2005. This is comprised primarily of accounting provisions related to pension
and post-retirement benefits not currently deductible for tax purposes, the
tax benefit of net operating loss carryforwards related to the UK operations
and share issue costs associated with the offering in relation to the
acquisition of the MOVA. The Company evaluates quarterly the ability to
realize its future tax assets. The factors used to assess the likelihood of
realization are the Company's forecast of future taxable income and available
tax planning strategies that could be implemented to realize the future tax
assets. The Company has available to it tax planning strategies to realize
future tax assets in order to avoid the potential loss of benefits.
Future tax liabilities of $36.8 million have been recorded at October 31,
2005. This liability is comprised primarily of tax depreciation in excess of
book depreciation.
The Company's tax filings are subject to audit by taxation authorities.
Although management believes that it has adequately provided for income taxes
based on the information available, the outcome of audits cannot be known with
certainty and the potential impact on the financial statements is not
determinable.

Employee Future Benefits

The Company provides pensions and post-retirement benefits, including
medical benefits and dental care. The determination of the obligation and
expense for defined benefit pensions and post-retirement benefits is dependent
on the selection of certain assumptions used by actuaries in calculating such
amounts. Those assumptions are disclosed in Note 13 to the Company's 2004
audited consolidated financial statements.

Risk Management

The following are updates to certain of the risks and uncertainties
described in the Management's Discussion and Analysis (MD&A) section of
Patheon's 2004 Annual Report, available on SEDAR (www.sedar.com) or on
Patheon's web site (www.patheon.com).

Foreign Currency

The Company's business activities are conducted in several currencies -
Canadian dollars and U.S. dollars for the Canadian operations, U.S. dollars
for the U.S. operations and euros and British sterling for the European
operations.
Since the European and U.S. operations conduct business principally in
their respective local currencies, the exposure to foreign currency gains and
losses is not significant. However, the Company's Canadian operations
negotiate sales contracts for payment in both U.S. and Canadian dollars, and
materials and equipment are purchased in both U.S. and Canadian dollars. The
majority of its non-material costs (including payroll, facilities' costs and
costs of locally sourced supplies and inventory) are denominated in Canadian
dollars. Approximately 65% to 75% of revenues of the Canadian operations and
approximately 15% to 25% of its operating expenses are transacted in U.S.
dollars. As a result, the Company may experience trading and translation gains
or losses because of volatility in the exchange rate between the Canadian and
U.S. dollar. Based on the Company's current U.S. denominated net inflows, for
each one-cent change in the Canadian-U.S. rate, the impact on annual earnings
per share is slightly less than one cent per share.
To mitigate this risk, the Company maintains net monetary asset and/or
liability balances in foreign currencies and engages in foreign currency
hedging activities using derivative financial instruments. The Company does
not purchase any derivative instruments for speculative purposes.
The Company has entered into forward exchange contracts to sell U.S.
dollars and purchase Canadian dollars. The mark-to-market value of these
financial instruments as at October 31, 2005 was an unrealized gain of
$0.2 million.
Translation gains and losses related to the carrying value of the
Company's foreign operations are deferred and included in the cumulative
translation account in shareholders' equity. At October 31, 2005, the balance
in the account was a $38.1 million gain compared with a $24.4 million gain at
October 31, 2004.

Additional Information

Share Capital

As of December 13, 2005, the Company had outstanding 92,845,688 common
shares and no remaining Class I preferred shares.

Public Securities Filings

Other information about the Company, including the annual information
form and other disclosure documents, reports, statements or other information
that is filed with Canadian securities regulatory authorities can be accessed
through SEDAR at www.sedar.com.

Outlook

The Company expects modest improvement in operating results in fiscal
2006, with the second half of the year stronger than the first. Net earnings
and earnings per share in 2006 are expected to be similar to 2005 levels,
excluding the impact of the one-time gain in the fourth quarter of 2005 and
the anticipated write-off of deferred financing costs and pre-payment
penalties in the first quarter of 2006.
The Company anticipates that the first quarter of 2006 will be impacted
by normal seasonality and production shutdowns, as well as lower production
levels caused by the temporary suspension of production of the Omnicef(R)
product that is expected to have an additional impact of approximately 3 cents
per share. In addition, the one-time write-off of deferred financing costs and
pre-payment penalties of approximately $7.6 million will have a one-time
negative impact on earnings. First-quarter results, before the impact of the
one-time write-off, will also reflect a full quarter of amortization,
depreciation and interest expenses related to the MOVA acquisition compared to
five weeks in the first quarter of 2005.
The Company expects 2006 to be a transition year. Initiatives for 2006
will include addressing the short-term challenges at MOVA, expanding
cephalosporin capacity in Swindon, completing the transfer of two groups of
products to the European operations, addressing the challenges faced by the
Canadian OTC sites including Whitby, expanding PDS operations in Puerto Rico
and establishing an initial PDS presence in India. The Company will also focus
on early stage and advanced stage opportunities for new business at both MOVA
and the other operations with a view to increasing production volumes in
fiscal 2007 and beyond.
The combination of oral cephalosporin capabilities at the Carolina
facility, the existing sterile cephalosporin capabilities at Swindon and the
new lyophilization plant dedicated to cephalosporin products that the Company
is constructing in Swindon will facilitate providing services in a full range
of dosage forms for this important category of antibiotics. The new facility
at Swindon, scheduled for completion by the end of fiscal 2006, represents an
investment of approximately 22 million euros. The client is providing a
substantial portion of the financing for this investment.
In Europe, the Company will continue to integrate new Rx products into
sites in Italy and France as part of the transfer of two groups of products
from two clients who are restructuring their respective facilities in Europe.
As part of this initiative, the Company will be establishing high-potency
capabilities in Bourgoin by investing approximately 10 million euros at this
site in 2006 and 2007.
In Canada, sites that focus on manufacturing OTC products are facing
significant challenges to achieve or maintain satisfactory levels of
profitability. This will be an area of particular focus for management in
fiscal 2006.
The Company expects to continue to expand its successful PDS operations
by focusing efforts on two new initiatives. In Puerto Rico, the Company will
expand existing PDS capabilities by encouraging clients to conduct PDS
research and development in a favourable tax jurisdiction. The Company also
expects to establish a presence in India to explore opportunities to provide
PDS services from that country. This initiative in India is not expected to
generate positive financial benefits in fiscal 2006.
In summary, the Company expects 2006 results to stabilize after a
difficult year in 2005. The Company anticipates growth rates and profitability
will improve in 2007 to the extent that its initiatives in 2006 are
implemented successfully.

No Auditor Review

Under National Instrument 51-102, Part 4, subsection 4.3 (3) (a), if an
auditor has not performed a review of the interim financial statements, they
must be accompanied by a notice indicating that the financial statements have
not been reviewed by an auditor.
The accompanying unaudited interim financial statements of the Company
have been prepared by and are the responsibility of management. The Company's
independent auditor has not performed a review of the financial statements for
the three-month and twelve-month periods ended October 31, 2005 or for the
comparative periods ended October 31, 2004.

FORWARD-LOOKING STATEMENTS

This news release and management discussion and analysis of financial
condition and results of operations ("MD&A") contains forward-looking
statements which reflect management's expectations regarding the Company's
future growth, results of operations, performance (both operational and
financial) and business prospects and opportunities. Wherever possible, words
such as "plans", "expects" or "does not expect", "forecasts", "anticipate" or
"does not anticipate", "believe", "intend" and similar expressions or
statements that certain actions, events or results "may", "could", "would",
"might" or "will" be taken, occur or be achieved have been used to identify
these forward-looking statements. Although the forward-looking statements
contained in this news release and MD&A reflect management's current
assumptions based upon information currently available to management and based
upon what management believes to be reasonable assumptions, the Company cannot
be certain that actual results will be consistent with these forward-looking
statements. Forward-looking statements necessarily involve significant known
and unknown risks, assumptions and uncertainties that may cause the Company's
actual results, performance, prospects and opportunities in future periods to
differ materially from those expressed or implied by such forward-looking
statements. These risks and uncertainties include, among other things: the
market demand for client products; dependence on key clients; the ability to
identify and secure new contracts; regulatory matters; management of expanded
operations; international operations risks; currency risks, competition;
product liability claims; the management of expanded operations; integration
of new operations; financing risks and interest rate risks. Although the
Company has attempted to identify important risks and factors that could cause
actual actions, events or results to differ materially from those described in
forward-looking statements, there may be other factors and risks that cause
actions, events or results not to be as anticipated, estimated or intended.
There can be no assurance that forward-looking statements will prove to be
accurate, as actual results and future events could differ materially from
those anticipated in such statements. Accordingly, readers should not place
undue reliance on forward-looking statements. These forward-looking statements
are made as of the date of this news release and MD&A and, except as required
by law, the Company assumes no obligation to update or revise them to reflect
new events or circumstances.

>>


Patheon Inc on 6ix

In the deck

Story so far

Earlier from Patheon

Later from Patheon

All Patheon news releases